Johnson & Johnson Shares Drop More Than 5% Despite Higher 2026 Outlook

Johnson & Johnson shares fell more than 5% Tuesday even as the healthcare company posted $25.399 billion in third-quarter sales and raised its full-year outlook. Sales increased 5.9% from a year earlier, while adjusted diluted earnings reached $2.59 per share. Reported diluted earnings were $0.09 per share after special charges tied to talc litigation, acquisitions and other items. MedTech was the main pressure point. Worldwide operational sales in the unit grew 2.5%, with Cardiovascular and Surgery performance outside the U.S. needing improvement. Physician selectivity also continued to weigh on ABIOMED. Innovative Medicine delivered stronger growth, with operational sales up 7.9%.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.